Evidence map›Paper›PMID 35750781›Full record

ArticleNPJ vaccines2022

Seasonal influenza vaccination expands hemagglutinin-specific antibody breadth to older and future A/H3N2 viruses.

Nina Urke Ertesvåg, Rebecca Jane Cox, Sarah Larteley Lartey, Kristin G-I Mohn, Karl Albert Brokstad, Mai-Chi Trieu

Open access · goldAbstract read
In one paragraph

Article in NPJ vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Nina Urke ErtesvågInfluenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway. nina.ertesvag@uib.no.ORCID http://orcid.org/0000-0001-5243-9101
Rebecca Jane CoxInfluenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway.ORCID http://orcid.org/0000-0002-8341-4078
Sarah Larteley LarteyInfluenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway.
Kristin G-I MohnInfluenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway.ORCID http://orcid.org/0000-0002-3249-1719
Karl Albert BrokstadInfluenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway.ORCID http://orcid.org/0000-0003-0593-2731
Mai-Chi TrieuInfluenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway. chi.trieu@uib.no.ORCID http://orcid.org/0000-0001-9181-5843
University of Bergen · NOHaukeland University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

History of influenza A/H3N2 exposure, especially childhood infection, shape antibody responses after influenza vaccination and infection, but have not been extensively studied. We investigated the breadth and durability of influenza A/H3N2-specific hemagglutinin-inhibition antibodies after live-attenuated influenza vaccine in children (aged 3-17 years, n = 42), and after inactivated influenza vaccine or infection in adults (aged 22-61 years, n = 42) using 14 antigenically distinct A/H3N2 viruses circulating from 1968 to 2018. We found that vaccination and infection elicited cross-reactive antibody responses, predominantly directed against newer or future strains. Childhood H3-priming increased the breadth and magnitude of back-boosted A/H3N2-specific antibodies in adults. Broader and more durable A/H3N2-specific antibodies were observed in repeatedly vaccinated adults than in children and previously unvaccinated adults. Our findings suggest that early A/H3N2 exposure and frequent seasonal vaccination could increase the breadth and seropositivity of antibody responses, which may improve vaccine protection against future viruses.

Identifiers

PMID35750781
PMCPMC9232600
OpenAlexW4283360591

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.